| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | X4 Pharmaceuticals, Inc | 11,494,437 | 6.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | X4 Pharmaceuticals, Inc | 1,600,136 | 0.9% | EDGAR |
| SC 13G | 2024-02-14 | ACORN BIOVENTURES, L.P. | X4 Pharmaceuticals, Inc | 8,205,816 | 4.8% | EDGAR |
| SC 13G/A | 2024-02-13 | Bain Capital Life Sciences Fund, L.P. | X4 Pharmaceuticals, Inc | 16,915,784 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-07 | BlackRock Inc. | X4 Pharmaceuticals, Inc | 8,160,747 | 4.9% | EDGAR |
| SC 13G | 2024-01-31 | BlackRock Inc. | X4 Pharmaceuticals, Inc | 8,417,524 | 5.0% | EDGAR |
| SC 13G/A | 2024-01-16 | MILLENNIUM MANAGEMENT LLC | X4 Pharmaceuticals, Inc | 1,664,317 | 1.0% | EDGAR |
| SC 13G/A | 2024-01-08 | Empery Asset Management, LP | X4 Pharmaceuticals, Inc | 4,549,605 | 2.6% | EDGAR |
| SC 13G | 2023-06-16 | MILLENNIUM MANAGEMENT LLC | X4 Pharmaceuticals, Inc | 8,268,816 | 5.2% | EDGAR |
| SC 13D/A | 2023-05-26 | Growth Equity Opportunities 18 VGE, LLC | X4 Pharmaceuticals, Inc | 15,742,792 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | X4 Pharmaceuticals, Inc | 650,000 | 1.3% | EDGAR |
| SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | X4 Pharmaceuticals, Inc | 1,172,223 | 1.7% | EDGAR |
| SC 13G/A | 2023-02-14 | ORBIMED ADVISORS LLC | X4 Pharmaceuticals, Inc | 10,328,649 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-14 | Bain Capital Life Sciences Fund, L.P. | X4 Pharmaceuticals, Inc | 12,202,510 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Ikarian Capital, LLC | X4 Pharmaceuticals, Inc | 349,133 | 0.3% | EDGAR |
| SC 13G | 2023-01-13 | Empery Asset Management, LP | X4 Pharmaceuticals, Inc | 6,198,684 | 5.1% | EDGAR |
| SC 13D/A | 2022-12-20 | Growth Equity Opportunities 18 VGE, LLC | X4 Pharmaceuticals, Inc | 12,136,793 | 10.0% | EDGAR |
| SC 13D | 2022-07-19 | Growth Equity Opportunities 18 VGE, LLC | X4 Pharmaceuticals, Inc | 6,878,157 | 9.9% | EDGAR |
| SC 13G/A | 2022-02-14 | Point72 Asset Management, L.P. | X4 Pharmaceuticals, Inc | 1,633,204 | 5.8% | EDGAR |
| SC 13G/A | 2022-02-14 | BIOTECHNOLOGY VALUE FUND L P | X4 Pharmaceuticals, Inc | 1,691,198 | 5.8% | EDGAR |